Next-Generation Retinal Disease Treatments: Advancing Care in nAMD and DME

Michael A. Klufas, MD, discusses how second-generation retinal vascular agents like high-dose aflibercept 8 mg and faricimab show promising results for treating neovascular AMD and diabetic macular edema, with particular emphasis on extended treatment intervals up to 20 to 24 weeks and strategies for managing persistent exudation while maintaining vision.